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Abstract: Health-care students can be exposed to biological risks during university training.
The persistence of long-term immunogenicity against hepatitis B virus (HBV) was analyzed in
a cohort of nursing students two decades after primary vaccination. A total of 520 students were
enrolled at the University of Palermo and were evaluated for levels of anti-HBsAg antibodies.
The students were examined during the first year of their Degree Course and were checked two years
later. All students with anti-HBsAg <10 mIU/mL during their first or third year were boosted within
one month. The proportion of students that were vaccinated during adolescence showing anti-HBsAg
≥10 mIU/mL was higher than that observed in students who were vaccinated during infancy (69%
versus 31.7%; p-value < 0.001). Receiving HBV vaccination at adolescence was significantly associated
with a fourfold increased possibility of having anti-HBsAg titers ≥10 mIU/mL (adj-OR = 4.21, 95%
CI: 2.43–7.30). Among the students who were checked at the third year and boosted after the first
year (n = 279), those who were vaccinated during infancy showed a higher percentage of antibody
titers <10 mIU/mL (20.3% versus 8.7% among vaccinated during adolescence; p < 0.01). This study
confirms that HBV vaccination at adolescence might determine a higher long-term persistence of
anti-HBsAg titers ≥10 mIU/mL and that anti-HBV booster could increase levels of anti-HBsAg over a
relatively short period, especially in subjects who were vaccinated during infancy.
Keywords: HBV infection; HBV vaccination; Anti-HBs titer; Healthcare students; work related
biological risk
1. Introduction
The World Health Organization (WHO) estimates that about 59 million health care workers
(HCWs) are exposed to multiple occupational hazards every day, the most common being the risk of
exposure to infected patients and/or infectious materials, including body fluids, contaminated medical
supplies and equipment, environmental surfaces, or air [1].
In particular, hepatitis B virus (HBV) represents the most transmissible blood-borne virus following
percutaneous exposure among healthcare workers [2].
Vaccines 2020, 8, 1; doi:10.3390/vaccines8010001 www.mdpi.com/journal/vaccines
Vaccines 2020, 8, 1 2 of 9
In Italy, according to the national law, healthcare students are considered workers and, therefore,
if they are exposed to physical, chemical, biological, or psychological risks, they should be examined
by an occupational health physician to evaluate the risks related to their practical activities [3].
Standard precautions, the adoption of enhanced percutaneous injury precautions, and HBV
vaccination of HCWs have been demonstrated to consistently reduce the risk of occupational infections
and prevent nosocomial transmission of the virus [4].
About 95% of the population who are vaccinated against HBV will develop an effective immune
response, which can be confirmed by the evaluation of antiHBsAg antibodies (protective level
≥10 mIU/mL) [5].
Some studies suggest that the acquired immunity persists for at least 10 years after vaccination
with antibody levels ≥10 mIU/mL, however probably not longer if vaccination was performed during
the neonatal age [6,7].
In Italy, universal and compulsory HBV vaccination was introduced in 1991 with a two-cohort
strategy [8]. In particular, since 1991, HBV vaccination was administered to infants and 12-year old
adolescents on a national scale [8].
In Italy, among subjects who were vaccinated against HBV from 1991 to 2003, higher immunization
levels were observed among those who were vaccinated during adolescence [9].
The 2017 to 2019 Italian National Vaccination Plan strongly recommends the active offer of HBV
vaccination to all healthcare professionals [10].
Several researches conducted among students attending healthcare courses highlighted the
importance of measuring the immunological response against HBV and of the need for a booster dose
in subjects with not protective values, since they have to be considered at higher risk of acquiring HBV
infection due to traineeships and/or internships in hospital units [11–16].
The main goal of this study was to evaluate persistence of long-term immunogenicity of anti-HBV
vaccination and to identify possible predictive factors associated with a stronger immunological
response to primary vaccination.
Moreover, a reassessment was carried out during the third year of the study course, two years
after the first examination, and levels of antiHBsAg were analyzed and discussed for students that
were boosted and those that were not.
2. Materials and Methods
From November 2015 to April 2019, a cohort of 520 students attending the nursing schools at the
University of Palermo, Italy was evaluated for serum HBsAg, anti-HBs, and anti-HBc. Students were
examined during their first and third academic years for evaluating occupational risks. The first-year
examination was conducted in 2015/2016, whereas the third-year examination was conducted during
2018/2019.
A standardized medical record including socio-demographic factors (age, gender, country of
origin), clinical information (relatives’ diseases and personal remote and proximate pathologies),
and previous HBV vaccination was filled-out for each student. Moreover, a medical examination and a
blood withdrawal were performed for each student.
Students who were negative for HBsAg and anti-HBc, with titers of anti-HBs lower than 10
mIU/mL, were subsequently boosted and the titer was reassessed after one month.
According to Italian law, a written informed consent was obtained from all the subjects [17].
The study was approved by the Ethical Committee of the University Hospital “P. Giaccone” of
Palermo (Protocol number 26/2016 of the 19th of October 2016).
All enrolled nursing students were previously vaccinated against HBV, they were HBsAg negative,
and none of them received a vaccination booster before the enrollment.
Among 520 students who were enrolled at the occupational examination for their first year,
449 were further evaluated at a follow-up visit at the third year and 71 were considered lost at follow-up
due to changing or dropping-out of the study course.
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The flow chart that is reported in Figure 1A,B describes the study population.
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Figure 1. (A) and (B). Students enrolled at occupational examinations conducted during the 1st (n = 520)
and 3rd year (n = 449) of the nursing study course.
All students with a titer ≤10 mIU/mL at the first visit (298 out of 436 vaccinated during infancy,
26 out of 84 vaccinated during adolescence) were boosted within one month.
After the booster, serop otecti n rates were si ilar in students who were v ccinated duri g
adolescence (92% of which 66.6% reporti g levels of anti-HBsAg ≥1000 mUI/mL) nd in those who
were vaccinated during infancy (94.1% of which 45.4% reporting levels of anti-HBsAg ≥1000 mUI/Ml).
At the third year of course, a higher p rcen age of students with ti- sAg <10 requir d a booster
a ong those who were vaccinated during infancy compared to those who were vaccinated during
adolescence, independently from ha ing received a booster dose at the first year of the study course
(20% versus 8.1%).
Vaccines 2020, 8, 1 4 of 9
2.1. Serological Tests
Serological analyses were performed with commercial chemiluminescence assays (VITROS
anti-HBs assay on the Vitros ECI Immunodiagnostic system, Ortho-Clinical Diagnostics, United
Kingdom).
In particular, the antibody to the hepatitis B surface antigen (anti-HBs) levels were expressed as
mIU/mL. A dynamic range of quantification is 10–1000 mIU/mL. A level of anti-HBs above 10 mIU/mL
was considered as protective against HBV infection.
2.2. Statistical Analysis
Absolute and relative frequencies were calculated for the categorical (qualitative) variables and
normally distributed quantitative variables were summarized by their means (standard deviations).
The differences in the categorical variables were analyzed using chi-squared tests (or Fisher’s exact test
when appropriate) and the Student t-test for the means.
All the variables that were found to have an association with protective Hepatitis B surface
antibody titers (≥10 mIU/mL) at the first visit were included in a multivariate backward stepwise
logistic regression model. Crude and adjusted OR with 95% confidence intervals (CIs) were also
calculated in the logistic regression model. All information were entered into a database created with
Excel 10.0. All data were analyzed using the statistical software package Stata/MP 12.1 (StataCorp LP,
College Station, USA).
3. Results
The main characteristics of the subjects that were included in the study are shown in Table 1.
A total of 520 students (n = 436 vaccinated during infancy, 83.8%; n = 84 vaccinated during adolescence,
16.2%) underwent an occupational examination during the first year of their degree course. The mean
age was 20.5 years (SD±1.6) for students who were vaccinated during infancy and 29.3 years (SD ± 4.9)
for students who were vaccinated during adolescence (p-value < 0.001). A higher percentage of female
students among those that were vaccinated during infancy (66.3% versus 59.5% among students
vaccinated during adolescence) was observed.
Table 1. General characteristics of the nursing students enrolled during the 1st year of the study course
(n = 520).
n = 520
Vaccination during
Infancy
(n = 436)
Vaccination during
Adolescence
(n = 84)
p-Value
Mean age ± DS 20.5 ± 1.6 29.3 ± 4.9 <0.001
Gender, n (%)
Male 147 (33.7) 34 (40.5)
0.14Female 289 (66.3) 50 (59.5)
Years from vaccination,
mean ± DS 20.5 ± 1.6 17.3 ± 4.9 <0.001
Anti-HBs titers, n (%)
<10 mIU/mL 298 (68.3) 26 (31.0)
<0.001≥10 mIU/mL 138 (31.7) 58 (69.0)
The mean of years passed from the primary cycle of HBV vaccination was significantly higher
among students who were vaccinated during infancy than among students vaccinated during
adolescence (20.5 ± 1.6 versus 17.3 ± 4.9; p-value < 0.001). Fifty-eight (69%) students who were
vaccinated during adolescence showed Hepatitis B surface antibody titers ≥10 mIU/mL, while the
prevalence of subjects with anti-HBs titers ≥10 mIU/mL among students vaccinated during infancy
was 31.7% (p-value < 0.001).
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In Table 2, the results of the univariate and multivariate analysis of factors associated with protective
levels of anti-HBs at first examination are reported. After adjustment for confounding variables,
receiving HBV vaccination during adolescence was significantly associated with increased possibilities
of having Hepatitis B surface antibody titers ≥10 mIU/mL (adj-OR = 4.21, 95% CI = 2.43–7.30). In the
multivariable analysis, years passed since the first HBV vaccination schedule and gender were not
significantly associated with higher anti-HBsAg values.
Table 2. Factors associated with protective Hepatitis B surface antibody titers (≥10 mIU/mL) at the first
year occupational examination among nursing students (n = 520).
Crude OR 95% CI p-Value AdjOR 95%CI p-Value
Years since HBV vaccination 0.87 0.81–0.93 <0.01 0.96 0.89–1.03 0.25
Gender
Male ref
0.60
ref
0.80
Female 0.90 0.62–1.31 0.95 0.64–1.40
HBV vaccination timing
vaccinated during infancy ref
<0.001
ref
<0.001
vaccinated during adolescence 4.81 2.90–7.97 4.21 2.43–7.30
In Table 3, the serological characteristics of the student cohort that was reassessed for HBV at
control examination conducted during the third year of the degree (n = 449) were reported. Subjects
vaccinated during infancy (n = 375) showed a higher percentage of anti-HBsAg <10mUI/mL (20%
versus 8.1% among those vaccinated during adolescence; p < 0.01). A higher percentage of students
with anti-HBsAg <10 mUI/mL was observed, although this was not significant when also considering
students boosted (20.3% versus 8.7% among those vaccinated during adolescence) and not boosted
after the first visit (19.3% versus 7.9% among those vaccinated during adolescence).
Table 3. Anti-HBs titers observed among nursing students during their occupational examination
during the third year of their study course (n = 449).
Vaccination during
Infancy
n (%)
Vaccination during
Adolescence
n (%)
p-Value
Anti-HBs titers at the control visit (third year), (n = 449)
<10 mIU/mL 75 (20.0) 6 (8.1)
<0.01
≥10 mIU/mL 300 (80.0) 68 (91.9)
Anti-HBs titers at the control visit (third year) among students not boosted after their first visit, (n = 170)
<10 mIU/mL 23 (19.3) 4 (7.9)
0.06
≥10 mIU/mL 96 (80.7) 47 (92.1)
Anti-HBs titers at the control visit (third year) among students boosted after their first visit, (n = 279)
<10 mIU/mL 52 (20.3) 2 (8.7)
0.18
≥10 mIU/mL 204 (79.7) 21 (91.3)
4. Discussion
Undoubtedly, during their practical training, students attending a medical degree course, such as
nursing students, can be professionally exposed to the risk of contracting infectious diseases as well as
HBV infection [2,18].
Several studies conducted on similar populations showed that subjects vaccinated at birth or
during adolescence maintain a protective antibody titer in the following 10 years in most cases,
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while the percentage is reduced 20 years after the primary vaccination schedule, especially if the
vaccination was performed during the neonatal age [9,19,20].
In particular, two recently published Italian studies found a lower proportion of subjects with
anti-HBs titre <10 mIU/mL than those observed in our cohort (37.7% in Palermo versus 30.8% in
Florence and 12% in Rome) [21,22]. These findings are quite different when also considering the time
of vaccination and a higher proportion of subjects with non-protective antibody titers was found in
our cohort, both considering subjects vaccinated during infancy (68.3% in Palermo versus 51% in
Florence and 22.8% in Rome) and subjects vaccinated during adolescence (31% in Palermo versus
12% in Florence and 10% in Rome) [21,22]. Unfortunately, mean age and intervals between primary
vaccination and antiHBs titers check seem to be quite similar between the different studies. To date,
the reasons for such differences are not clear to us and further investigations are required. On the other
hand, in all three settings, vaccination during adolescence elicited higher anti-HBs titres compared to
vaccinations performed during infancy.
The different immunological response that was observed among young healthcare professionals
who were vaccinated during infancy and during adolescence could be, at least in part, attributable
not only to the maturity of the immune response system at the time of the first vaccination cycle
completion, but also to the lower dosage contained in the neonatal anti-HBV vaccines compared to
some vaccines administered during adolescence [23].
This study seems to confirm these findings and shows that after adjusting for years passed since
the first vaccination, statistically significantly higher anti-HBsAg values were observed among nursing
students vaccinated during adolescence.
Moreover, the rate of anti-HbsAg antibody titer <10 mIU/mL was surprisingly higher in the cohort
of subjects who were vaccinated during infancy that were boosted two years before (n = 52, 69.3% of
subjects with anti-HBsAg <10 mIU/mL at the third year of the study course), also suggesting that after
anti-HBV booster, subjects that are vaccinated during infancy could rapidly decrease their anti-HBsAg
levels below 10mIU/mL.
In Italy, several studies have demonstrated a low endemic level of HBV (prevalence of HBsAg in
the general population <2%), with an incidence of about 1 case per 100,000 individuals and this result
is indubitably attributable to the universal vaccination strategies adopted in 1991 [8,24].
The epidemiology of HBV in developed countries suggests that healthcare workers, and in
particular, healthcare students, could have a low risk of contracting the disease, despite not being
negligible [25]. For these reasons, to date in Italy, for healthcare professionals as well as for medical
residents, students, and trainees, the vaccination against HBV is actively strongly recommended and is
free of charge, however there are no mandatory anti-HBV vaccination booster policies [10].
The results of the present study confirm that among the boosted subjects, different responses
could be observed and, generally, there was a significant correlation between higher levels of anti-HBs
after booster and protective anti-HBs titers after two years.
This correlation was also observed, even though it was not statistically significantly, between high
baseline levels of anti-HBs and anti-HBs titers ≥10 mIU/mL after two years. These two correlations
were independent from the primary administration of the HBV vaccination schedule.
Future studies that analyze the modification of anti-HBs levels over time for not boosted and
boosted healthcare workers could take these results into consideration.
Moreover, the data obtained in this study could also help to further clarify the effect of the HBV
vaccination booster, demonstrating a rapid antibody response from the primary vaccination cycle
several years later in subjects that were originally responders [25].
Even though to date, a large majority of Italian healthcare students, trainees, medical residents,
and workers ≤39 years old have been vaccinated according to the national immunization schedule,
a standardized screening for HBV, provided by Occupational Medicine services, it is fundamental not
only to identify subjects with low levels of anti-HBsAg or non-responders after primary vaccination
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cycle, but also for detecting HCWs older than 40-years-old that have not been vaccinated at birth or at
12 years of age.
In this sense, it should be noted that the Italian Legislation recommends the administration of an
HBV booster dose for health care workers with anti-HbsAg antibody titer <10 mIU/mL [26].
At first, this recommendation seems to conflict with the World Health Organization position paper
on Hepatitis B vaccines, suggesting that subjects with an anti-HBs titer <10 mIU/mL still retain immune
memory and therefore, a booster dose in the routine immunization schedule is not recommended [27].
Our results confirm that once the presence of immunological memory in these subjects is
demonstrated, regardless of the decline observed in a limited group of boosted subjects two years
before, it would no longer make sense to retest them periodically for anti-HBsAg in health surveillance
protocols [28,29].
Moreover, despite declining serum levels of anti-HBsAg, international evidences show that
vaccine-induced immunity continues to prevent clinical disease or detectable HBV infection [30].
Unfortunately, this study could have some limitations. A first possible limitation is due to the
relatively small sample size, which could have reduced the relevance of the statistical tests in finding
statistically significant differences. A second limitation is the lack of data about the first vaccination
schedule (mostly type of vaccine, etc.). Moreover, the presence of some students lost to laboratory
follow-up could have introduced a potential selection bias.
Despite the presence of these possible limitations, our findings confirm the expected reduction of
anti-HBsAg two decades after the HBV primary vaccination schedule, which was more evident in
subjects who were vaccinated during infancy due to a probable immaturity of the immune system at
that time or to the use of a vaccine with lower antigenic content [31].
5. Conclusions
This study confirms that HBV vaccination during adolescence might determine a higher long-term
persistence of anti-HBsAg titers ≥10mIU/mL and that HBV booster could increase levels of anti-HBsAg
over a relatively short period, especially in subjects who were vaccinated during infancy.
Moreover, more than two-thirds of the subjects vaccinated during infancy showed levels of
anti-HBsAg <10 mIU/mL at the first visit and after having developed a valid immunity one month
after the booster dose, among 20% of students boosted two years earlier, anti-HBsAg levels were again
<10 mIU/mL at the control visit (third year).
It is highly likely that when encountering the natural HBV virus, subjects who were vaccinated
or boosted that showed anti-HBsAg levels <10 mIU/mL at the first or third visit will produce a valid
antibody reaction that is capable of antagonizing the infection.
These findings support the recommendation by the regulatory Health Agencies to screen and
administer a booster dose for first time individuals belonging to high-risk groups, such as professionals
employed in health-care services, and in future, could represent a suggestion for the management of
health-care workers vaccinated against HBV during infancy or adolescence according to their anti-HBs
immunization status [32].
In future, it could be useful to increase the number of subjects enrolled in the study to confirm
and increase the generalizability of our results, identifying other variables that could play a further
role in determining the seroconversion rate and perdurance of antibody levels.
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